Landsteiner has restructured its debt and received an equity injection from BID Group
Landsteiner Scientific has completed the successful restructuring of US$190 million of debt under Chapter 11 and has received an equity injection of US$ 20 million from BID Group.
Founded in 1998, Landsteiner is a Mexican pharmaceutical company leader on the development, manufacture and distribution of generic and biotechnological healthcare products. The company operates two state-of-the-art pharmaceutical plants. Landsteiner has over 100 registered molecules from 16 different therapeutic areas and has over 200 different product presentations.
BID Group is an investment fund founded in Mexico City. The group consists of seven business units successfully built over the past 25 years: payroll loan, financial services, IT projects, energy/power supply, construction and operation of infrastructures, venture capital and medical supply solutions.
Oaklins’ team in Mexico acted as the financial advisor to Landsteiner Scientific in the debt restructuring as well as in the structuring of the stock acquisition by BID Group.
Talk to the deal team
Related deals
Pharma-Skan & Skan-Medic have been acquired by Brygge Partners
Pharma-Skan, an independent contract manufacturing organization (CMO), and Skan-Medic, a manufacturer of over-the-counter (OTC) products, both operating as a joint entity, have been acquired by Brygge Partners.
Learn moreHe-Man Dual Controls has been acquired by Lagercrantz UK Limited
Lagercrantz UK Limited has acquired 100% of the shares in HM Holding Limited (He-Man Dual Controls), a leader in supplemental control systems for vehicles.
Learn moreManolete Partners plc has completed a successful debt refinancing
Manolete Partners plc has signed a new revolving credit facility (RCF) with its existing provider, HSBC. The new RCF provides Manolete with the same level of facility as the previous arrangement, at US$22.6 million (£17.5 million), but with a reduced margin and lower non-utilization fee. The facility has a term of 3.25 years, with the option to extend for an additional year on the same terms.
Learn more